USSTOCK.TODAY
Market Closed
Log in Sign up

CRISPR Therapeutics draws attention to CTX310 cardiovascular disease treatment clinical data

The Motley Fool +1 · ·by G4L

CRSP
CRSP CRISPR Therapeutics AG
$40.37 -4.43%
View chart & analysis →
  1. 1CRISPR Therapeutics reported Phase 1a clinical data in August.
  2. 2CTX310 showed an average TG reduction of 48% and an average LDL reduction of 53% at the highest dose.
  3. 3CRISPR Therapeutics is scheduled to report Phase 1b clinical data in early November.

So what's the key point?

CRISPR Therapeutics announced clinical trial results for a cardiovascular disease treatment. The drug showed an effect of lowering blood fat levels by 53%, so the next trial results are also drawing attention.

Source The Motley Fool +1 · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →